Eckert+Ziegler: Q3 review: a stronger dose of earnings - NuWays AG Research
EUZ's Q3 earnings recovery provides a firmer base for year-end delivery, with therapeutic isotopes offering substantial medium-term growth potential at a modest valuation of c. 8x FY26e EV/EBITDA.
ANNONS
EUZ's Q3 earnings recovery provides a firmer base for year-end delivery, with therapeutic isotopes offering substantial medium-term growth potential at a modest valuation of c. 8x FY26e EV/EBITDA.